Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
EPA CPDat observed this chemical in 98 composition records across product categories including Laboratory supplies, Pet and animal care, Specialty occupational products.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 5/100 (low) · high confidence.
Prevalence of SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE in our catalog (epa_cpdat).
Products
98
Catalog
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
EPA
EPA CPDat observed this chemical in 98 composition records across product categories including Laboratory supplies, Pet and animal care, Specialty occupational products.
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION; Maximum daily exposure: 14 mg
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
hello watermelon mouthwash
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
US
FDA
Route: INTRALESIONAL; Dosage form: INJECTION; Maximum daily exposure: 14 mg
US
FDA
Route: INTRALESIONAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 120 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 1.84 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 15.55 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION, EXTENDED RELEASE; Maximum daily exposure: 30 mg
US
FDA
Route: INTRASYNOVIAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
US
FDA
Route: INTRAVASCULAR; Dosage form: INJECTION; Potency: 0.15 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION; Maximum daily exposure: 120 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 13.61 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 15.55 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 27 mg
US
FDA
Route: INTRAVESICAL; Dosage form: SOLUTION; Potency: 0.12 mg
US
FDA
Route: INTRAVITREAL; Dosage form: INJECTION; Potency: 0.86 %w/v
US
FDA
Route: INTRAVITREAL; Dosage form: INJECTION, SUSPENSION; Potency: 0.04 %w/v
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION; Maximum daily exposure: 4 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION/ DROPS; Maximum daily exposure: 8 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION; Potency: 0.04 %w/w
US
FDA
Route: ORAL; Dosage form: INJECTION; Potency: 10.06 mg
US
FDA
Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 1500 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 104 mg
US
FDA
Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Potency: 35 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED; Potency: 0.11 mg
US
FDA
Route: SOFT TISSUE; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Maximum daily exposure: 2 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: SUSPENSION; Potency: 0.07 %w/v
US
FDA
Route: TOPICAL; Dosage form: CREAM; Maximum daily exposure: 10 mg
US
FDA
Route: TOPICAL; Dosage form: LOTION; Maximum daily exposure: 8 mg
US
FDA
Route: TOPICAL; Dosage form: LOTION, AUGMENTED; Maximum daily exposure: 10 mg
US
FDA
Route: TOPICAL; Dosage form: SOLUTION; Potency: 0.46 %w/v
US
FDA
FDA NDC lists this ingredient in 48 active drug products and 49 total products.
US
FDA
openFDA substance registry classifies this ingredient as chemical.